Table 1. Demographic, Genotype, and Ocular Status of Study Participants (n=249) at Study Baseline

Age, years, mean±SD		33.3±13.5
Sex, n (%)	Male	121(49%)
	Female	128(51%)
Race (self-reported), n (%)	Asian	3(1%)
	Black	6(2%)
	Hispanic	15(6%)
	White	222(90%)
	Other	3(3%)
Genotype category of germline VHL mutation, n (%)	Total genotyped	240(96%)
	Missense mutations	115(48%)
	Protein-truncating mutations	101(42%)
	Complete gene deletions	12(5%)
	Other (splice mutations, amino acid deletion mutations)	12(5%)
Ocular VHL disease, n (%)	None	95(38%)
	Present	154(62%)
	One eye involved	72(29%)
	Both eyes involved	82(33%)
Age of onset, years, mean±SD		25.2±12
Prior treatment for ocular VHL disease, n eyes (%)		142(29%)
Mean BCVA, letters, mean±SD	Better-seeing eye	85.5±11.3
	Worse-seeing eye	67.9±32.5

Key: SD = standard deviation, VHL = von Hippel-Lindau, BCVA = best corrected visual acuity